Rapport Therapeutics to Present New Phase 2a Data Analysis Further Characterizing RAP-219 in Focal Onset Seizures at 2025 American Epilepsy Society Annual Meeting
Rapport Therapeutics, Inc. (RAPP)
Company Research
Source: GlobeNewswire
BOSTON and SAN DIEGO, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today announced that the Company will present the results of its Phase 2a trial of RAP-219 in focal onset seizures (FOS), along with new efficacy analysis, at the upcoming 2025 American Epilepsy Society (AES) Annual Meeting, taking place December 5–9, 2025, in Atlanta. The Company will present during the meeting’s poster sessions and will also host a dedicated Scientific Exhibit Room highlighting the RAP-219 clinical program. In addition to topline efficacy and safety data from its Phase 2a FOS trial, new data on RAP-219’s effect during the first month of treatment and consistency of efficacy over the entire treatment period, the effect of baseline disease severity on efficacy out
Show less
Read more
Impact Snapshot
Event Time:
RAPP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RAPP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RAPP alerts
High impacting Rapport Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
RAPP
News
- Rapport Therapeutics Announces New Data and Post Hoc Analysis Demonstrating the Magnitude and Consistency of RAP-219’s Clinical Response in Patients with Focal Onset SeizuresGlobeNewswire
- Wall Street Analysts See a 74.99% Upside in Rapport Therapeutics, Inc. (RAPP): Can the Stock Really Move This High? [Yahoo! Finance]Yahoo! Finance
- Rapport Therapeutics (NASDAQ:RAPP) was upgraded by analysts at BTIG Research to a "strong-buy" rating.MarketBeat
- Rapport Therapeutics (NASDAQ:RAPP) is now covered by analysts at BTIG Research. They set a "buy" rating and a $47.00 price target on the stock.MarketBeat
- Rapport Therapeutics (NASDAQ:RAPP) had its price target raised by analysts at Citizens Jmp from $77.00 to $80.00. They now have a "market outperform" rating on the stock.MarketBeat
RAPP
Earnings
- 11/6/25 - Beat
RAPP
Sec Filings
- 12/1/25 - Form 4
- 11/18/25 - Form 4
- 11/18/25 - Form 4
- RAPP's page on the SEC website